banda transcan 2 2016ul

Title: Exploiting the peptidome of atypical teratoid/rhabdoid tumors - characterization of novel tumor-associated antigens for immunotherapy in order to maintain long-term remissions.


Project Coordinator:
Matthias EYRICH (Germany) University Children's Hospital, Wurzburg

Project Partners:
Hans-Georg RAMMENSEE (Germany) Interfakultares Institut for Zellbiologie, Universität Tubingen, Tubingen
Yair REISNER (Israel) Weizman Institute of Science, Rehovot
Stefaan VAN GOOL (Belgium) KU Leuven, Leuven

Project Abstract:
Atypical teratoid/rhabdoid tumors (ATRT) are rare but highly malignant neuroectodermal tumors with a peak incidence in early childhood and a characteristic biallelic mutation in the SMARCB1 gene. ATRTs show a highly aggressive course. Although intense treatment regimens have been succesful in inducing primary remissions in a substantial number of patients, relapses are frequent and almost inevitably fatal.
Therefore, innovative relapse prevention strategies are urgently needed. Active immunotherapy represents an attractive option in this regard. Currently, initial attempts using dendritic cells loaded with tumor lysate are carried out and first results are encouraging. Since tumor lysate is a mixture of unknown antigens, we want to analyze the ATRT-peptidome by directly eluting peptides from tumor HLA-molecules and sequence analysis via mass spectrometry. Subsequently, the most relevant peptides will be tested for  Subsequently, the most relevant peptides will be tested for immunogenicity in naïve CD8+ T cells from healthy donors and selected patients. Frequency of intrinsic immune responses against these peptides will be tested in ATRT patients as well as in non-cancer affected carriers of the SMARCB1 mutation. These data will directly lead to a clinical trial with patient-specific peptide pools, the preparation of which will be the last milestone of this project. In summary, our proposal will not only provide new information about the ATRT-peptidome and thus pave the way for a recurrence prevention trial. It will also contribute to our knowledge about immunosurveillance in non-cancer affected mutation carriers of tumor suppressor genes.

Final summary:
AT/RT tumors of the CNS are highly aggressive tumors especially in small children which respond to chemo- and radiotherapy but often relapse. Immunotherapy could be a useful and targeted strategy to improve long-term remission control. Results from other cancer entities have shown that the immunogenic target structures of tumors are highly individual and vary with the extent of genetic alterations. AT/RT are known for their very low number of mutations per tumor, but no data on the AT/RT ligandome are available so far. In this project, we collected samples from 23 AT/RT tumors so far and are currently analyzing the HLA-ligandome of these tissues. In the mass-spectrometric analyses, a total of 54 MHC class I and 151 MHC class II tumor-exclusive ligands could be identified. Analyses regarding immunogenicity of these candidate peptides are under way. Furthermore, we compared MHC binding affinity and immunogenicity of these tumor-specific peptides with identifiable neoantigens from the same tumors. Ligandome peptides showed superior MHC-binding affinities compared to theoretically predicted neoepitopes, confirming their suitability for immunotherapy.

 

Published article:
Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Ana Marcu, Andreas Schlosser, Anne Keupp, Nico Trautwein, Pascal Johann, Matthias Wölfl, Johanna Lager, Camelia Maria Monoranu, Juliane S Walz, Lisa M Henkel, Jürgen Krauß, Martin Ebinger, Martin Schuhmann, Ulrich Wilhelm Thomale, Torsten Pietsch, Erdwine Klinker, Paul G Schlegel, Florian Oyen, Yair Reisner, Hans-Georg Rammensee, Matthias Eyrich.
J Immunother Cancer, 2021 Oct;9(10):e003404.
PMID: 34599019 DOI: 10.1136/jitc-2021-003404

 

(Project funded under JTC 2013)


TRANSCAN News

 TRANSCAN-3 news on:
twitter logoinkedin social media logo

TRANSCAN-3   JOINT TRANSNATIONAL CALL 2022 on:
 "Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy"  

is open for submission

Please visit the TRANSCAN-3 website at
https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl


Other news:

The Digital Institute for Cancer Outcomes Research (DIGICORE),  is delighted to announce an innovative new training programme for early career researchers in oncology: IDEAL4RWE.
 Please register for an introductory webinar on the19th April 2022(https://lnkd.in/ez7y4kWU).
Brochure for more details: https://tinyurl.com/y7aurdtk


 The first TRANSCAN-3 call (JTC 2021) on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"
is closed for submission

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

Newsletters

The TRANSCAN-3 newsletters are published at: https://www.transcan.eu/

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter


All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 9 guests and no members online